>> HOMEPAGE

Measles

Routine high-dose vitamin A therapy for children hospitalized with measles.

Hussey GD; Klein M
J Trop Pediatr 1993 Dec;39(6):342-5

Measles is without specific therapy and remains important globally as a cause of childhood death. In controlled studies, high-dose vitamin A therapy (Hi-VAT)--with 400,000 IU vitamin A--has been demonstrated to markedly reduce measles-associated morbidity and mortality. We performed a retrospective study of the hospital records of 1720 children < 15 years of age who were hospitalized for measles, to determine the extent to which these findings, in research settings, are applicable to the case management of measles under conditions of routine hospital practice. The outcomes were studied of children hospitalized during two non-consecutive 2 year periods (1985-6 and 1989-90). A policy of Hi-VAT for all children hospitalized with measles was started during the intervening period. As compared with the group of children on standard therapy (n = 1061), children receiving Hi-VAT (n = 651) had a shorter hospital stay (mean 10 versus 13 days; P < 0.001), a lower requirement for intensive care (4.3 versus 10.5 per cent; P < 0.001), and a lower death rate (1.6 versus 5 per cent; P < 0.001). No adverse effects of Hi-VAT therapy were observed. We conclude that a policy of high dose oral vitamin A (400,000 IU) supplementation in measles provides benefits which are equivalent to those previously observed only in controlled research trials, that it is highly cost effective, and that it should form part of the routine case management of all children hospitalized with measles.

Sitemap

Was ist neu:

Ignaz Semmelweis: Zuerst von seinen Kollegen belächelt, später als Held gefeiert

Beenden Sie die Verdammung der Naturheilkunde! – Offener Brief von Dr. Matthias Rath an Bundeskanzlerin Angela Merkel

Prof. Edzard Ernst: Karriere durch Verunglimpfung von Naturheilverfahren?

Für eine gerechtere Welt – ohne Armut und Volkskrankheiten

William Harvey – ein Arzt der verstand, dass er seiner Zeit voraus war

Herber Rückschlag für die Biotech-Industrie: Insekten entwickeln Resistenzen gegenüber Gen-Pflanzen

» Natürliche Gesundheit

» "Geschäft m. d. Krankheit"

» Internationale Kampagne

» Dr. Raths Offene Briefe

» Studien weltweit

» Studien auf Deutsch

» Helfen Sie mit!

» Codex Alimentarius

» Dossiers

» Sitemap

Dr. Rath Health Foundation auf Facebook Dr. Rath Health Foundation auf YouTube Dr. Rath Health Foundation auf Twitter RSS
 © 2017 Dr. Rath Health Foundation | Kontakt | Impressum | RSS Feed